The team at STAT picked this NYT piece on the opiod crisis as one of the top stories of the year.
Surprising absolutely no one, McKinsey made a buck from it
'Opana’s manufacturer, the pharmaceutical company Endo, had scaled back promotion of the drug. But months later, the company abruptly changed course, refocusing resources on the drug by assigning more sales representatives.
The push was known internally as the Sales Force Blitz — and it was conducted with consultants at McKinsey & Company, who had been hired by Endo to provide marketing advice about its chronic-pain medicines and other products.'